On the stock market since 2015, it operates in the world of health and science. It has 1 employee. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 100% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
The price looks reasonable next to what the company earns.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It met or beat analyst expectations in 6 of the last 7 quarters — consistency is a promise kept.
A loss of $1.0M against $0 in annual sales. And on top of that, sales fell from the year before.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 15/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 28/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, SYBX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SYBX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.